When Osimertinib was paired with VRT752271, an ERK inhibitor, the combination therapy displayed a much more potent effect in decreasing the survival of EGFR-mutant NSCLC cell lines [62]. Here, MAPK1 is linked to non-small cell lung carcinoma.